Graeme Semple

USPTO Granted Patents = 21 (Patent Applications = 6)

CIPO Patents = 2 (Patent Applications = 6)

EPO Patents = 11 (Patent Applications = 15)

Average Co-Inventor Count = 6.1

ph-index = 5

Forward Citations = 99(Granted Patents)

Company Filing History:

21 out of 216

Arena Pharmaceuticals, Inc.

patents

2 out of 1,535

Boehringer Ingelheim International Gmbh

where one patent can have more than one assignee

Years Active: 2006-2024

Loading Chart...

21 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12115157 - 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament (2024-10-15),

2. 11780827 - Substituted 3-phenoxyazetidin-1-yl-pyrazines (2023-10-10),

3. 11608339 - 5-HT2C receptor agonists and compositions and methods of use (2023-03-21),

4. 11395824 - 5-HTreceptor agonists and compositions and methods of use (2022-07-26),

5. 10836764 - 5-HT2C receptor agonists and compositions and methods of use (2020-11-17),

6. 10624900 - 5-HTreceptor agonists and compositions and methods of use (2020-04-21),

7. 10392390 - 5-HTreceptor agonists and compositions and methods of use (2019-08-27),

8. 10272094 - 5-HT2C receptor agonists and compositions and methods of use (2019-04-30),

9. 9676758 - 1-heteroaryl-indoline-4-carboxamides as modulators of GPR52 useful for the treatment or prevention of disorders related thereto (2017-06-13),

10. 9365511 - Biphenyl-ethyl-pyrrolidine derivatives as histamine H3 receptor modulators for the treatment of cognitive disorders (2016-06-14),

11. 8933083 - 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia (2015-01-13),

12. 8637555 - Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof (2014-01-28),

13. 8546429 - 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto (2013-10-01),

14. 8410119 - Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto (2013-04-02),

15. 8293751 - 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia (2012-10-23),

Certainly! Here is an article about inventor Graeme Semple:

Title: Graeme Semple: Bridging Innovation and Medicine

Introduction:

Graeme Semple, a visionary inventor based in San Diego, California, is renowned for his groundbreaking work in the field of pharmaceuticals. With a passion for innovation and a relentless drive to push the boundaries of technology, Semple has cemented his legacy as a true pioneer in the world of inventions.

Latest Patents:

Semple's latest patents include the development of Substituted 3-phenoxyazetidin-1-yl-pyrazines, which are crucial in treating central nervous system diseases. Additionally, he has pioneered 5-HT2C receptor agonists, opening new avenues for the treatment of various disorders, including weight management and psychiatric conditions.

Career Highlights:

With an impressive portfolio of 20 patents to his name, Semple has made significant contributions to the pharmaceutical industry. His work has not only revolutionized treatment approaches but has also laid the foundation for future advancements in medicine.

Collaborations:

Throughout his career, Semple has collaborated with esteemed organizations such as Arena Pharmaceuticals, Inc. and Merck & Company, Inc. His partnerships with colleagues like Albert S Ren and Yifeng Xiong have led to innovative solutions that have reshaped the landscape of pharmacology.

Conclusion:

In conclusion, Graeme Semple's unwavering dedication to innovation and his transformative inventions have not only propelled the field of medicine forward but have also inspired generations of inventors and innovators. His legacy serves as a testament to the power of persistence and ingenuity in driving meaningful change in the world of pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.